A 31-year-old woman with a transformed low-grade glioma

JAMA

Volumn 303, Issue 10, 2010, Pages 967-976

  Warnke, Peter C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOMA; HUMAN; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PERIOPERATIVE PERIOD; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; STEREOTACTIC BIOPSY; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TUMOR LOCALIZATION; WADA TEST; BRAIN TUMOR; CANCER STAGING; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGODENDROGLIOMA; PROGNOSIS;

EID: 77949321562     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.222     Document Type: Article

References (94)

1. Krainik A, Lehericy S, Duffau H, et al. Postoperative speech disorder after medial frontal surgery: role of the supplementary motor area. Neurology. 2003; 60(4):587-594.
2. Steinmeier R, Sobottka SB, Reiss G, Bredow J, Gerber J, Schackert G. Surgery of low-grade gliomas near speech-eloquent regions: brainmapping versus preoperative functional imaging. Onkologie. 2002;25(6):552-557.
3. Ahmed Z, Muzaffar S, Kayani N, Pervez S, Husainy AS, Hasan SH. Histological pattern of central nervous system neoplasms. J Pak Med Assoc. 2001;51(4): 154-157.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumors of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2007.
5. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006;106(6):1358-1363.
6. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009;472: 323-342.
7. Michotte A, Neyns B, Chaskis C, Sadones J, In 't Veld P. Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta Neurol Belg. 2004; 104(4):148-153.
8. Hoshino T. A commentary on the biology and growth kinetics of low-grade and high-grade gliomas. J Neurosurg. 1984;61(5):895-900.
9. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53(4):524-528.
10. Shafqat S, Hedley-Whyte ET, Henson JW. Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology. 1999;52(4):867-869.
11. Kreth FW, Faist M, Grau S, Ostertag CB. Interstitial 125I radiosurgery of supratentorial de novo WHO grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer. 2006;106(6):1372-1381.
12. Weber MA, Giesel FL, Stieltjes B. MRI for identification of progression in brain tumors: from morphology to function. Expert Rev Neurother. 2008;8(10):1507-1525.
13. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50(5):1316-1322.
14. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46(12):1948-1958.
15. Pöpperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47(3):393-403.
16. Pauliah M, Saxena V, Haris M, Husain N, Rathore RK, Gupta RK. Improved T(1)-weighted dynamic contrast-enhanced MRI to probe microvascularity and heterogeneity of human glioma. Magn Reson Imaging. 2007;25(9):1292-1299.
17. Rodriguez FJ, Perry A, Gutmann DH, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008; 67(3):240-249.
18. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24(8):1236-1245.
19. Johannesen TB, Langmark F, Lote K. Cause of death and long-term survival in patients with neuro-epithelial brain tumours: a population-based study. Eur J Cancer. 2003;39(16):2355-2363.
20. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489.
21. Macdonald DR. Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Semin Oncol. 1994;21(2):236-248.
22. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997; 15(4):1294-1301.
23. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43(5):1066-1073.
24. van den Bent MJ. Chemotherapy of oligodendroglial tumours: current developments. Forum (Genova). 2000;10(2):108-118.
25. Walker C, du Plessis DG, Fildes D, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res. 2004;10(21):7182-7191.
26. Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008;66(3):262-272.
27. Německová J, Nemecek S, Nahlovsky J, Parizek J, Sercl M. Epilepsy associated with low-grade brain glial neoplasms. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1995;38(4):175-183.
28. Lombardi D, Marsh R, de Tribolet N. Low grade glioma in intractable epilepsy: lesionectomy versus epilepsy surgery. Acta Neurochir Suppl. 1997;68: 70-74.
29. Brodsky MC, Boop FA. Lid nystagmus as a sign of intrinsic midbrain disease. J Neuroophthalmol. 1995;15(4):236-240.
30. Bowers DC, Georgiades C, Aronson LJ, et al. Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatr Neurosurg. 2000;32(1):24-29.
31. Edvardsson T, Ahlstrom G. Illness-related problems and coping among persons with low-grade glioma. Psychooncology. 2005;14(9):728-737.
32. Reijneveld JC, van der Grond J, Ramos LM, Bromberg JE, Taphoorn MJ. Proton MRS imaging in the follow-up of patients with suspected low-grade gliomas. Neuroradiology. 2005;47(12):887-891.
33. Fan GG,DengQL,WuZH,GuoQY. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol. 2006;79(944):652-658.
34. Derlon JM, Chapon F, Noel MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27(7):778-787.
35. Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging. 2002;16(3):229-237.
36. Rijpkema M, Schuuring J, van der Meulen Y, et al. Characterization of oligodendrogliomas using short echo time 1HMRspectroscopic imaging. NMR Biomed. 2003;16(1):12-18.
37. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64(3):227-237.
38. Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M. Delineation of gliomas with magnetic resonance imaging using gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol. 1990; 31(5):417-429.
39. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27(7):1432-1437.
40. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000;48(1):43-52.
41. Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB. 11C-methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir. 2007;68(1):19-23.
42. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784-1791.
43. Stieber VW. Low-grade gliomas. Curr Treat Options Oncol. 2001;2(6): 495-506.
44. Yamini B, Sikorski CW. Surgery for low-grade gliomas: current evidence and controversies. Expert Rev Neurother. 2005;5(6)(suppl):S13-S19.
45. Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D; Medscape. Surgery insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol. 2007;3(11):628-639.
46. Johannesen TB, Langmark F, Lote K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg. 2003;99(5):854-862.
47. Duffau H. New concepts in surgery ofWHOgrade II gliomas: functional brain mapping, connectionism and plasticity-a review. J Neurooncol. 2006;79(1): 77-115.
48. Berger MS, Ghatan S, Haglund MM, Dobbins J, Ojemann GA. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg. 1993;79(1):62-69.
49. Berger MS. Functional mapping-guided resection of low-grade gliomas. Clin Neurosurg. 1995;42:437-452.
50. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95(5):735-745.
51. Schramm J, Blumcke I, Ostertag CB, Schlegel U, Simon M, Lutterbach J. Lowgrade gliomas-current concepts. Zentralbl Neurochir. 2006;67(2):55-66.
52. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating lowgrade gliomas. Neurosurgery. 2008;63(4):700-708.
53. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the longterm outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8): 1338-1345.
54. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549-556.
55. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of lowversus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002; 20(9):2267-2276.
56. van den Bent MJ, Afra D, de Witte O, et al; EORTC Radiotherapy and Brain Tumor Groups and UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990.
57. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007;14(4):391-398.
58. Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003; 14(12):1722-1726.
59. Tosoni A, Franceschi E, Ermani M, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive lowgrade gliomas. J Neurooncol. 2008;89(2):179-185.
60. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009;15(1):330-337.
61. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7): 1277-1280.
62. Rossi GF, Scerrati M, Roselli R. Epileptogenic cerebral low-grade tumors: effect of interstitial stereotactic irradiation on seizures. Appl Neurophysiol. 1985; 48(1-6):127-132.
63. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43(8):1599-1601.
64. Knisely JP, Rockwell S. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am. 2002;12(4):525-536.
65. Vitaz TW, Warnke PC, Tabar V, Gutin PH. Brachytherapy for brain tumors. J Neurooncol. 2005;73(1):71-86.
66. Kiebert GM, Curran D, Aaronson NK, et al; EORTC Radiotherapy Cooperative Group. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer. 1998;34(12):1902-1909.
67. Scerrati M, Roselli R, Iacoangeli M, Pompucci A, Rossi GF. Prognostic factors in low grade(WHOgrade II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry. 1996;61(3):291-296.
68. Lo SS, Cho KH, Hall WA, et al. Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas? Int J Cancer. 2001;96(suppl):71-78.
69. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-764.
70. Voges J, Treuer H, Schlegel W, Pastyr O, Sturm V. Interstitial irradiation of cerebral gliomas with stereotactically implanted iodine-125 seeds. Acta Neurochir Suppl (Wien). 1993;58:108-111.
71. Kreth FW, Faist M, Warnke PC, Rossner R, Volk B, Ostertag CB. Interstitial radiosurgery of low-grade gliomas. J Neurosurg. 1995;82(3):418-429.
72. Voges J, Sturm VV V. Interstitial irradiation with stereotactically implanted I-125 seeds for the treatment of cerebral glioma. Crit Rev Neurosurg. 1999;9(4): 223-233.
73. Scerrati M, Montemaggi P, Iacoangeli M, Roselli R, Rossi GF. Interstitial brachytherapy for low-grade cerebral gliomas: analysis of results in a series of 36 cases. Acta Neurochir (Wien). 1994;131(1-2):97-105.
74. Mehrkens JH, Kreth FW, Muacevic A, Ostertag CB. Long term course ofWHO grade II astrocytomas of the insula of reil after I-125 interstitial irradiation. J Neurol. 2004;251(12):1455-1464.
75. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003; 97(5):1276-1284.
76. Paleologos NA. Chemotherapy for low-grade gliomas. Expert Rev Neurother. 2005;5(6)(suppl):S21-S24.
77. Dropcho EJ. Low-grade gliomas in adults. Curr Treat Options Neurol. 2004; 6(4):265-271.
78. Agulnik M, Mason WP. The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol Oncol Clin North Am. 2006;20(6): 1249-1266.
79. Nimsky C, Ganslandt O, Buchfelder M, Fahlbusch R. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res. 2006;28(5):482-487.
80. Schramm J, Aliashkevich AF. Surgery for temporal mediobasal tumors: experience based on a series of 235 patients. Neurosurgery. 2008;62(6)(suppl 3): 1272-1282.
81. Yamada K, Goto S, Kochi M, Ushio Y. Stereotactic biopsy for multifocal, diffuse, and deep-seated brain tumors using Leksell's system. J Clin Neurosci. 2004; 11(3):263-267.
82. Brown PD, Buckner JC, Uhm JH, Shaw EG. The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro Oncol. 2003;5(3):161-167.
83. Laack NN, Brown PD, Ivnik RJ, et al; North Central Cancer Treatment Group. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005;63(4):1175-1183.
84. Kreth FW, Faist M, Rossner R, Birg W, Volk B, Ostertag CB. The risk of interstitial radiotherapy of low-grade gliomas. Radiother Oncol. 1997;43(3):253-260.
85. Friedman HS, Lovell S, Rasheed K, Friedman AH; Writing Committee for the Brain Tumor Center at Duke. Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Med Pediatr Oncol. 1998; 31(1):16-18.
86. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007;82(3):281-288.
87. Goerne R, Bogdahn U, Hau P. Procarbazine-a traditional drug in the treatment of malignant gliomas. Curr Med Chem. 2008;15(14):1376-1387.
88. Akai T, Ueda Y, Sasagawa Y, et al. High mobility group I-C protein in astrocytoma and glioblastoma. Pathol Res Pract. 2004;200(9):619-624.
89. Mardor Y, Last D, Daniels D, et al. Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009;330(2):520-525.
90. Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010;6(1):117-125.
91. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Δ24-RGD to human gliomas. Cancer Res. 2009;69(23):8932-8940.
92. Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29(4):486-493.
93. Walker C, Haylock B, Husband D, et al. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. Br J Cancer. 2006;95(10):1424-1431.
94. Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology. 2006;48 (10):703-713.